Karen K. Mcginnis net worth and biography

Karen Mcginnis Biography and Net Worth

CAO of Illumina

Mrs. Karen K. McGinnis has been Vice President and Chief Accounting Officer of Illumina, Inc. since November 14, 2017. Mrs. McGinnis served as the Chief Executive Officer and President of Mad Catz Interactive Inc. from February 5, 2016 to March 30, 2017. Mrs. McGinnis served as the Chief Financial Officer of Mad Catz Interactive Inc. since June 10, 2013 and served as its Principal Accounting Officer. She served as the Chief Accounting Officer, Corporate Controller and Vice President of Cymer, Inc. from November 30, 2009 to May 30, 2013. She served as the Chief Accounting Officer of Insight Enterprises Inc. from September 2006 to March 31, 2009 and its Assistant Secretary from January 2005 to March 31, 2009. She served as Senior Vice President of Finance of Insight Enterprises Inc. since April 2001 and also served as its Senior Vice President. Mrs. McGinnis joined Insight Enterprises, Inc. in March 2000 as its Vice President of Finance. From 1997 to 2000, she served as the Chief Financial Officer of Horizon. From 1989 to 1997, Mrs. McGinnis was employed by KPMG LLP and served as its Senior Assurance Manager. She served as a Director of Mad Catz Interactive Inc. from February 5, 2016 to March 30, 2017. Mrs. McGinnis is a Certified Public Accountant and received her Bachelor of Science degree in Accounting from the University of Oklahoma.

What is Karen K. Mcginnis' net worth?: The estimated net worth of Karen K. Mcginnis is at least $2.04 million as of July 26th, 2021. Ms. Mcginnis owns 15,000 shares of Illumina stock worth more than $2,040,300 as of December 22nd. This net worth estimate does not reflect any other assets that Ms. Mcginnis may own. Learn More about Karen K. Mcginnis' net worth.
How do I contact Karen K. Mcginnis?: The corporate mailing address for Ms. Mcginnis and other Illumina executives is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. Illumina can also be reached via phone at (858) 202-4500 and via email at [email protected]. Learn More on Karen K. Mcginnis' contact information.
Has Karen K. Mcginnis been buying or selling shares of Illumina?: Karen K. Mcginnis has not been actively trading shares of Illumina over the course of the past ninety days. Most recently, Karen K. Mcginnis sold 218 shares of the business's stock in a transaction on Wednesday, November 18th. The shares were sold at an average price of $300.00, for a transaction totalling $65,400.00. Following the completion of the sale, the chief accounting officer now directly owns 1,538 shares of the company's stock, valued at $461,400. Learn More on Karen K. Mcginnis' trading history.
Who are Illumina's active insiders?: Illumina's insider roster includes Alexander Aravanis (SVP), Frances Arnold (Director), Charles Dadswell (SVP), Francis deSouza (CEO), Phillip Febbo (SVP), Jay Flatley (Director), Aimee Hoyt (SVP), Karen Mcginnis (CAO), Robert Ragusa (SVP), Mostafa Ronaghi (SVP), Sam Samad (CFO), Jacob Thaysen (CEO), Susan Tousi (SVP), and Mark Van Oene (SVP). Learn More on Illumina's active insiders.
Are insiders buying or selling shares of Illumina?: In the last year, Illumina insiders bought shares 1 times. They purchased a total of 7,330 shares worth more than $991,675.70. The most recent insider tranaction occured on February, 22nd when CEO Jacob Thaysen bought 7,330 shares worth more than $991,675.70. Insiders at Illumina own 0.2% of the company. Learn More about insider trades at Illumina.
Information on this page was last updated on 2/22/2024.

Karen K. Mcginnis Insider Trading History at Illumina

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/18/2020	Sell	218	$300.00	$65,400.00	1,538
11/6/2020	Sell	312	$310.10	$96,751.20	2,184
8/10/2020	Sell	1,856	$357.01	$662,610.56	2,350

Karen K. Mcginnis Buying and Selling Activity at Illumina

Illumina Company Overview

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Today's Range

Now: $136.02

$133.08

$137.69

50 Day Range

MA: $143.91

$130.74

$155.15

2 Week Range

Now: $136.02

$100.08

$156.66

Volume

14,354,048 shs

Average Volume

2,058,953 shs

Market Capitalization

$21.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.